Effect of Soy Protein Isolate Supplementation on Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy A Randomized Trial

被引:48
作者
Bosland, Maarten C. [1 ,5 ,8 ]
Kato, Ikuko [3 ,4 ]
Zeleniuch-Jacquotte, Anne [7 ]
Schmoll, Joanne [5 ]
Rueter, Erika Enk [1 ]
Melamed, Jonathan [6 ]
Kong, Max Xiangtian [6 ]
Macias, Virgilia [1 ]
Kajdacsy-Balla, Andre [1 ]
Lumey, L. H. [9 ]
Xie, Hui [2 ]
Gao, Weihua [2 ]
Walden, Paul [8 ]
Lepor, Herbert [8 ]
Taneja, Samir S. [8 ]
Randolph, Carla [5 ]
Schlicht, Michael J. [1 ]
Meserve-Watanabe, Hiroko [5 ]
Deaton, Ryan J. [1 ]
Davies, Joanne A. [5 ]
机构
[1] Univ Illinois, Dept Pathol, Coll Med, Chicago, IL 60612 USA
[2] Univ Illinois, Sch Publ Hlth, Dept Epidemiol & Biostat, Chicago, IL 60612 USA
[3] Wayne State Univ, Sch Med, Dept Oncol, Detroit, MI USA
[4] Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA
[5] NYU, Sch Med, Dept Environm Med, New York, NY USA
[6] NYU, Sch Med, Dept Pathol, New York, NY USA
[7] NYU, Sch Med, Dept Populat Hlth, New York, NY USA
[8] NYU, Sch Med, Dept Urol, New York, NY 10003 USA
[9] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2013年 / 310卷 / 02期
关键词
PHASE-II TRIAL; HPLC ANALYSIS; ANTIGEN; MEN; ISOFLAVONES; CONSUMPTION; PHYTOESTROGENS; TISSUE; RISK; CHEMOPREVENTION;
D O I
10.1001/jama.2013.7842
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE Soy consumption has been suggested to reduce risk or recurrence of prostate cancer, but this has not been tested in a randomized trial with prostate cancer as the end point. OBJECTIVE To determine whether daily consumption of a soy protein isolate supplement for 2 years reduces the rate of biochemical recurrence of prostate cancer after radical prostatectomy or delays such recurrence. DESIGN, SETTING, AND PARTICIPANTS Randomized, double-blind trial conducted from July 1997 to May 2010 at 7 US centers comparing daily consumption of a soy protein supplement vs placebo in 177 men at high risk of recurrence after radical prostatectomy for prostate cancer. Supplement intervention was started within 4 months after surgery and continued for up to 2 years, with prostate-specific antigen (PSA) measurements made at 2-month intervals in the first year and every 3 months thereafter. INTERVENTION Participants were randomized to receive a daily serving of a beverage powder containing 20 g of protein in the form of either soy protein isolate (n=87) or, as placebo, calcium caseinate (n=90). MAIN OUTCOMES AND MEASURES Biochemical recurrence rate of prostate cancer (defined as development of a PSA level of >= 0.07 ng/mL) over the first 2 years following randomization and time to recurrence. RESULTS The trial was stopped early for lack of treatment effects at a planned interim analysis with 81 evaluable participants in the intervention group and 78 in the placebo group. Overall, 28.3% of participants developed biochemical recurrence within 2 years of entering the trial (close to the a priori predicted recurrence rate of 30%). Among these, 22 (27.2%) occurred in the intervention group and 23 (29.5%) in the placebo group. The resulting hazard ratio for active treatment was 0.96 (95% CI, 0.53-1.72; log-rank P = .89). Adherence was greater than 90% and there were no apparent adverse events related to supplementation. CONCLUSION AND RELEVANCE Daily consumption of a beverage powder supplement containing soy protein isolate for 2 years following radical prostatectomy did not reduce biochemical recurrence of prostate cancer in men at high risk of PSA failure.
引用
收藏
页码:170 / 178
页数:9
相关论文
共 46 条
  • [1] Adams KF, 2004, CANCER EPIDEM BIOMAR, V13, P644
  • [2] [Anonymous], 2006, Dietary Reference Intakes The Essential Guide to Nutrient Requirements
  • [3] Stability of serum total and free prostate specific antigen under varying storage intervals and temperature
    Arcangeli, CG
    Smith, DS
    Ratliff, TL
    Catalona, WJ
    [J]. JOURNAL OF UROLOGY, 1997, 158 (06) : 2182 - 2187
  • [4] BARNES S, 1995, J CELL BIOCHEM, P181
  • [5] TREATMENT ALLOCATION PROCEDURE FOR SEQUENTIAL CLINICAL-TRIALS
    BEGG, CB
    IGLEWICZ, B
    [J]. BIOMETRICS, 1980, 36 (01) : 81 - 90
  • [6] Bektic Jasmin, 2005, Clin Prostate Cancer, V4, P124, DOI 10.3816/CGC.2005.n.021
  • [7] Franke AA, 1998, P SOC EXP BIOL MED, V217, P263, DOI 10.3181/00379727-217-44231
  • [8] FRANKE AA, 1995, P SOC EXP BIOL MED, V208, P18, DOI 10.3181/00379727-208-43826
  • [9] Gamache PH, 1998, P SOC EXP BIOL MED, V217, P274
  • [10] Greenlee H, 2004, J ALTERN COMPLEM MED, V10, P660, DOI 10.1089/acm.2004.10.660